
Algeta appoints Dr Andreas Menrad as chief scientific officer
pharmafile | August 19, 2013 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |Â Â Algeta, Genzyme, SanofiÂ
Norwegian cancer specialist Algeta has appointed Dr Andreas Menrad as its new chief scientific officer (CSO) and member of the executive management team.
In this newly created role, Dr Menrad will be responsible for developing and executing the company’s research strategy, including its Targeted Thorium Conjugate platform.
Dr Menrad will report directly to Andrew Kay, Algeta’s president and chief executive, and takes up this position immediately.
Dr Menrad brings more than 20 years of experience in the pharma and biotech industry, with a background in oncology therapeutic development. He joins Algeta from Ablynx, where he was also CSO.
Prior to this, Dr Menrad spent five years at Genzyme (Sanofi) in Cambridge, UK, where most recently he held the role of general manager and VP of antibody therapeutics.
Related Content

Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria
Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee …

Sanofi’s treatment granted orphan designation for rare chronic inflammatory condition
The European Medicines Agency has granted orphan designation to Sanofi’s investigational Bruton’s tyrosine kinase (BTK) …

Sanofi completes acquisition of Vigil Neuroscience to early neurology pipeline
Sanofi has announced that it has finalised its acquisition of Vigil Neuroscience, a US-based biotechnology …






